 "Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma")
Amidst a heated debate surrounding the approval of Covaxin, Bharat Biotech's Covid-19 vaccine candidate, the Hyderabad based firm on Thursday said that it has completed recruitment of 25,800 people for its phase 3 efficacy trial.
The last leg of enrolment for the trials happened in the last week of December, with the company saying it was half-way through for its recruitment target. On January 2 the company had informed that it has recruited 23,000 volunteers. The efficacy data is expected around March and over 5000 people have already received both the shots of the vaccine.
The subject expert committee (SEC)
